Skip to main content
Livermore
Livermore
ZHEN

4D Molecular Therapeutics, Inc.

FDMT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001650648

In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of FDMT: Q4 2025 compared with Q1 2026
MeasureQ4 2025Of which not filed for Q1 2026Q1 2026Change
Holders1532153+2
Shares53.4M3.09M50.7M+343.0K (+0.7%)
Value$400.5M$23.2M$471.4M+$94.1M (+24.9%)

2 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to FDMT in Q1 2026
InstitutionSharesValue% of portfolio
Vanguard Capital Management LLC2,195,578$20.4M0.00%
Trails Edge Capital Partners, LP1,302,917$12.1M2.85%
Vanguard Portfolio Management LLC555,829$5.17M0.00%
Propel Bio Management, LLC380,420$3.58M2.26%
Vanguard Fiduciary Trust Co269,295$2.51M0.00%
Exome Asset Management LLC130,564$1.22M0.72%
Opaleye Management Inc.112,291$1.05M0.14%
Simplify Asset Management Inc.70,430$655.7K0.01%
Voya Investment Management LLC45,359$422.3K0.00%
Quadrature Capital Ltd32,524$302.8K0.00%
Vanguard Global Advisers, LLC32,248$300.2K0.00%
Virtu Financial LLC26,368$245.0K0.01%
Y-Intercept (Hong Kong) Ltd25,420$236.7K0.00%
State of Wisconsin Investment Board22,956$213.7K0.00%
Simplex Trading, LLC21,660$201.7K0.01%
Headlands Technologies LLC15,956$148.6K0.02%
nVerses Capital, LLC10,069$93.7K0.09%
Group One Trading, L.P.1,998$18.6K0.00%
Northwestern Mutual Wealth Management Co1,094$10.2K0.00%
UBS Asset Management Americas Inc691$6.43K0.00%
Allworth Financial LP509$4.74K0.00%
Fortitude Family Office, LLC56$5210.00%
Fifth Third Bancorp35$3260.00%
US Bancorp35$3260.00%
MAI Capital Management18$1680.00%
Root Financial Partners, LLC11$1020.00%
Advisory Services Network, LLC8$740.00%
Rothschild Investment LLC6$560.00%

Sold out (26)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of FDMT in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Point72 Asset Management, L.P.1,539,860$11.5M
Baker Bros. Advisors LP475,737$3.57M
Two Sigma Advisers, LP275,300$2.06M
Silverarc Capital Management, LLC100,000$750.0K
Millennium Management LLC96,364$722.7K
Walleye Capital LLC50,762$380.7K
Decheng Capital LLC44,311$332.3K
Jain Global LLC40,464$303.5K
Jump Financial, LLC33,830$253.7K
Tudor Investment Corp Et Al31,815$238.6K
Axq Capital, LP30,755$230.7K
Harbor Capital Advisors, Inc.29,716$223.0K
Thrivent Financial for Lutherans28,938$217.0K
PDT Partners, LLC20,097$150.7K
Polymer Capital Management (US) LLC18,035$135.3K
DnB Asset Management AS16,123$120.9K
Quest Partners LLC15,731$118.0K
SG Americas Securities, LLC15,531$116.0K
Impact Partnership Wealth, LLC15,123$113.4K
Skopos Labs, Inc.13,318$102.3K
Trexquant Investment LP13,229$99.2K
Gabelli Funds LLC12,000$90.0K
Daiwa Securities Group Inc.6,370$48.0K
Torren Management, LLC2,361$17.7K
Amalgamated Bank1,261$9.00K
Caitong International Asset Management Co., Ltd214$1.60K

Not filed for Q1 2026 yet (2)

Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding FDMT in Q4 2025 that haven't filed for Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
Vanguard Group Inc3,093,527$23.2M
Comerica Bank35$263